CompletedPhase 2NCT01525082
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Studying Zollinger-Ellison syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shaheen Shagufta
- Principal Investigator
- Shaheen Shagufta, MDStanford University
- Intervention
- Capecitabine(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2019
Study locations (1)
- Stanford University Medical Center, Stanford, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01525082 on ClinicalTrials.govOther trials for Zollinger-Ellison syndrome
Additional recruiting or active studies for the same condition.